Figure 5From: The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trialsMigraine-Specific Questionnaire (MSQ) domain scores at end point (last observation carried forward) for pooled intent-to-treat subjects with ≥ 50% or < 50% reductions in monthly migraine frequency.Back to article page